Cardio3 Biosciences gains preferred access to all Mayo Clinic regenerative medicine portfolio

8 October 2014

Belgium biotech firm Cardio3 BioSciences (Euronext Brussels: CARD), says it has signed a preferred access agreement with the USA’s Mayo Clinic.

Under this accord, Mayo grants Cardio3 BioSciences preferred access to technologies developed in the Mayo Clinic Center for Regenerative Medicine, as well as select other Mayo technologies. This agreement is an expansion of a long-standing collaboration, which led to the development of C-Cure; Cardio3 BioSciences’ product candidate now in advanced clinical trial testing (Phase III); an innovative cell therapy based on the discovery of the cardiopoiesis platform by the team of Andre Terzic, at Mayo Clinic.

Mayo Clinic has identified regenerative medicine as a strategic priority and launched the Mayo Clinic Center for Regenerative Medicine, led by Dr A Terzic. The center is designed to discover, translate, and apply regenerative technologies across medical and surgical specialties.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK